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Available online xxxxBackground: Left atrial (LA) size predicts cardiovascular outcome in chronic heart failure. Its prognostic value in
adults with repaired tetralogy of Fallot (ToF) is unknown. This study therefore investigated the association of LA
size and function with cardiovascular events in adults with ToF.
Methods: Clinically stable adultswith ToFwhovisited the outpatient clinic between2011 and2013underwent echo-
cardiography andwereprospectively followed for theoccurrence of death, heart failure, hospitalizations, arrhythmia,
thromboembolic events, and re-interventions. LA maximal, minimal and pre-A wave volume, area and length were
measured on the apical four-chamber view. Total, passive and active emptying fractions were calculated.
Results: In total, 134 patients were included (median age 35 [IQR 29–45] years, 65% male, 91% NYHA I). Median
follow-up was 40 [IQR 32–47] months. Patients with a dilated LA (≥34 mL/m2, 43%) were at higher risk of
cardiovascular events (n= 33, adjusted HR 2.48 [1.09–5.62], P=0.030). Analysis of LA volumes as continuous var-
iables yielded similar conclusions. In addition, LA length (adjusted HR 2.49 [1.51–4.09], P b 0.001), total emptying
fraction (adjusted HR 0.96 [0.93–0.99], P = 0.008), and active emptying fraction (adjusted HR 0.92 [0.87–0.96],
P = 0.001) were signiﬁcantly associated with cardiovascular events. Standardized HRs indicated that LA length
was the strongest prognostic marker. In addition, none of the patients with a normally sized LA died or developed
heart failure.
Conclusions: LA size and function can provide relevant prognostic information in clinically stable adultswith repaired
ToF. Especially LA length may be a valuable additional tool in the risk stratiﬁcation of these patients.





Tetralogy of Fallot (ToF) is the most common cyanotic heart defect
[1,2]. Thanks to successful repair at young age, the survival of patients
with ToF has tremendously improved with current survival rates over
90% up to 30 years after surgical repair [3]. Nevertheless, residual lesions
are common. Especially older patients are at risk of complications such
as heart failure, arrhythmia and early demise. Therefore, life-long
follow-up is warranted. Identiﬁcation of patients with a high risk of
adverse cardiovascular events is essential, in order to optimize patient
information, follow-up and therapeutic strategies [3,4].
Echocardiography is the cornerstone in the evaluation of cardiac
function in patients with ToF. Right and left ventricular function are
known as important prognostic markers in these patients [5]. Atrial
function has been largely neglected so far. The left atrium (LA) hasedical Center, Department of
dam, The Netherlands.
elink).
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3multiple functions: it modulates as a reservoir, a conduit and as a
pump [6]. LA size can be reliablymeasuredwith two-dimensional echo-
cardiography and reﬂects the average effect of left ventricle (LV) ﬁlling
pressures over time. It is known as a useful marker for both chronicity
and severity of LV diastolic dysfunction [7–9]. Larger LA volumes have
been associated with an increased risk of adverse cardiovascular events
in patients with chronic heart failure [10]. To the best of our knowledge,
the prognostic value of LA size or function in patients with ToF has not
been evaluated. Therefore, the aim of this study was to investigate
the association of LA size and function with a composite endpoint of
cardiovascular events in clinically stable adults with repaired ToF.2. Methods
2.1. Study design and population
For the purpose of this study, all patients with repaired ToF were
selected from a large prospective cohort of clinically stable adults withsize and function in adults with tetralogy of Fallot, Int J Cardiol (2017),
2 V.J.M. Baggen et al. / International Journal of Cardiology xxx (2017) xxx–xxxcongenital heart disease. This cohort consisted of consecutive patients
who routinely visited our adult congenital cardiology outpatient clinic
and underwent echocardiography between April 2011 and April 2013.
Patients with pulmonary valve atresia and ventricular septal defect
and patients with isolated pulmonary stenosis were excluded. Other
exclusion criteriawere: age b18 years, pregnancy, incapability of under-
standing and signing informed consent, kidney failure (creatinine
N200 μmol/L), or insufﬁcient echocardiographic image quality. Image
qualitywas deﬁned as insufﬁcientwhen the LA borders were not clearly
visible and therefore could not be adequately traced in the apical four-
chamber (A4C) view.
At the time of study inclusion, all patients underwent physical
examination by a cardiologist, 12-lead ECG, venous blood sampling,
and echocardiography. Patient demographics, medical history, medica-
tion use, symptoms and signs of heart failure (NYHA classiﬁcation),
results of physical examination, associated lesions, surgical characteris-
tics, re-interventions, electrocardiography, echocardiography, laboratory
results and events were collected using an electronic CRF-based online
system (© 2004–2012 OpenClinica, LLC and collaborators). Details
have been reported previously [11]. The institutional review board
of the Erasmus MC approved the study protocol and all participants
provided written informed consent.
2.2. Echocardiography
Two-dimensional transthoracic echocardiographic images were
acquired using a commercially available ultrasound system iE33
(Philips Medical Systems, Best, the Netherlands) with a 1.5-MHz
transducer. Echocardiographic measurements were performed in
agreement with the current recommendations of the American Society
of Echocardiography and European Association of Cardiovascular
Imaging [12]. LV end-diastolic and end systolic volumeswere calculated
using the biplane method of disks summation (modiﬁed Simpson's
rule). LV systolic function was quantiﬁed with LV ejection fraction,
and visually graded as normal or impaired. LV diastolic function was
assessed using pulsed waved Doppler of the mitral valve inﬂow (E/A-
ratio and deceleration time) and septal tissue Doppler imaging (E’
wave and E/E’-ratio). RV systolic function was quantiﬁed with RV
fractional area change and tricuspid annular plane systolic excursion.
2.3. Left atrial size and function
LA volumetric measurements were performed on the A4C view in
three different phases during one cardiac cycle. LA maximal and mini-
mal volumewere measured on the frames with respectively the largest
and smallest atrial cavities on visual assessment. LA pre-A-wave volume
was measured one frame before the atrial contraction started (also
based on the movement of the mitral valve leaﬂets, and the onset of
the P-wave on the ECG). Contours were manually traced, the atrial
appendage and pulmonary veins were excluded, and at the mitral
valve level the contour was closed with a straight line. For the calcula-
tion of volumes a single plane summation of disks method was used.
In addition, left atrial maximal size was quantiﬁed using the LA
anteroposterior dimension on the parasternal long axis view, the LA
major axis on the A4C view (LA length), and the LA maximal area on
the A4C view (Supplemental File 1). All LA volumes were indexed by
body surface area.
We separately considered LA reservoir, conduit and contractile func-
tion [6,7,13]. Reservoir function was quantiﬁed with LA total emptying
volume (TEV), LA total emptying fraction (TEF) and the expansion
index. TEVwas calculated by LAmaximal volume - LAminimal volume.
TEF was calculated by (TEV/LA maximal volume) *100%. Expansion
indexwas deﬁned as (TEV/LAminimal volume) *100%. Conduit function
was quantiﬁed with LA passive emptying volume (PEV) and LA passive
emptying fraction (PEF). PEVwas calculated by LAmaximal volume - LA
pre-A-wave volume. PEF was calculated by (PEV/LA maximal volume)Please cite this article as: V.J.M. Baggen, et al., Prognostic value of left atrial
http://dx.doi.org/10.1016/j.ijcard.2017.02.153*100%. Contractile or active function was estimated with LA active
emptying volume (AEV) and LA active emptying fraction (AEF). AEV
was calculated by LA pre-A-wave volume - LA minimal volume. AEF
was calculated by (AEV/LA pre-A-wave volume) *100%.
One investigator (A.S.), who was blinded for clinical events and
other patient data, performed all LA measurements. Reproducibility
was assessed by blinded repeated analysis of 20 randomly selected
patients by the ﬁrst and a second observer (V.B.).
2.4. Laboratory testing
Peripheral venous blood samples were obtained from all patients
after at least 30 minutes of rest. Serum NT-proBNP was measured for
research purposes only in our clinical chemistry laboratory using a com-
mercial electrochemiluminescence immunoassay (Roche Diagnostics,
Rotkreuz, Switzerland). The limit of detection was 0.6 pmol/L. The
upper limit of normal for NT-proBNP was 14 pmol/L (approximately
125 pg/mL), based on the recommended low cut-off for the diagnosis
of heart failure in patients presenting with non-acute symptoms [14].
2.5. Deﬁnition and assessment of events
The primary endpointwas deﬁned prior to the collection of data as a
composite of all adverse cardiovascular events: all-cause mortality,
heart failure (requiring initiation or change in heart failure medication,
or requiring hospital admission), hospitalization for cardiac reasons,
arrhythmia (symptomatic and recorded, or requiring treatment),
thromboembolic events (ischemic cerebrovascular accident, pulmonary
embolism or myocardial infarction), or cardiac re-interventions
(surgical or percutaneous). A secondary composite endpoint of all-
cause mortality or heart failure was deﬁned. All patients were
prospectively followed for fatal and non-fatal events by a yearly clinical
evaluation at our institution. During the follow-up, patients were
treated according to the physician's discretion and the study protocol
did allow for adjustment of cardiac medication. Where necessary, we
retrieved information from electronic patient charts and correspon-
dence with referring hospitals. Survival status of all patients was also
checked in the Municipal Population Register. Events were adjudicated
by two experienced investigators (V.B. and J.R.) without knowledge of
LA measurements. The investigators had direct access to the patient
clinical records and the events were independently reviewed by each
investigator. For patients with multiple events, event-free survival was
deﬁned as the time from enrollment to the occurrence of the ﬁrst
event. Patients without any cardiovascular event were censored at the
end of the follow-up duration (August 1, 2015).
2.6. Statistical analysis
Continuous normally distributed data were presented as mean ±
standard deviation (SD) and skewed data asmedian [IQ1− IQ3]. Categor-
ical data were presented as frequencies and percentages. Following the
guidelines, patients were stratiﬁed according to LA volume index
b34 mL/m2 (normal LA) and ≥34 mL/m2 (dilated LA) [12]. Continuous
variableswere compared between these two groups using the Student's
t-test or the Mann-Whitney U test, depending on the distribution of
data. Categorical variables were compared using the Chi-squared test
or Fisher's exact test when applicable. Cumulative endpoint free
survival estimates and survival curves were derived by the Kaplan-
Meier method; the log-rank test was used to compare groups. Cox
proportional hazards regression was used to investigate the associa-
tions between LA measurements and endpoints. LA measurements
were analyzed as continuous and as standardized variables (created
by calculating z-scores). The association of LA measurements with the
primary endpoint was adjusted for age and NYHA functional class,
using a minimum of ten endpoints per degree of freedom to prevent
overﬁtting. Inter- and intra-observer agreement of LAmaximal volume,size and function in adults with tetralogy of Fallot, Int J Cardiol (2017),
3V.J.M. Baggen et al. / International Journal of Cardiology xxx (2017) xxx–xxxarea and length were presented by Bland-Altman plots. Limits of
agreement were deﬁned as the mean difference of the two repeated
measurements ±1.96 SD. The coefﬁcient of variation (COV) was
deﬁned as the SD of the differences of two measurements divided by
the mean of two measurements *100%. Mean relative differences were
calculated by dividing the difference of two measurements by the
mean of two measurements *100%. All data analysis was performed
using IBM SPSS Statistics Version 21.0.0.1 (IBM Corp., Armonk,




Of the 179 patients that were included in the initial cohort, 31
patients with pulmonary valve atresia and 1 patient with isolated
pulmonary stenosis were excluded. In addition, 13 patients were
excluded because of insufﬁcient image quality. These patients did not
have signiﬁcant or clinically relevant differences in age, NYHA classiﬁca-
tion, body mass index, use of cardiac medication or number of
re-interventions compared to the 134 adult patients with repaired ToF
who were included in this study. Median age at inclusion was 35 [29–
45] years and 87 patients (65%) were male. Median age at initial repairTable 1
Baseline characteristics of the study cohort.
Valid cases, n (%) All patients
Clinical characteristics
Age, years 134 (100) 35 [29–45]
Sex, male n (%) 134 (100) 87 (65)
NYHA class II-III, n (%) 134 (100) 12 (9)
Body mass index, kg/m2 134 (100) 24 ± 4
Body surface area, m2 134 (100) 1.89 ± 0.20
Systolic blood pressure, mmHg 131 (98) 126 ± 17
O2 saturation b90%, n (%) 126 (94) 1 (1)
Cardiac medication, n (%) 134 (100) 31 (23)*
ACE-inhibitor 134 (100) 10 (8)
Beta blocker 134 (100) 17 (13)
Anti-arrhythmic 134 (100) 10 (8)
Aspirin 134 (100) 10 (8)
Anticoagulants 134 (100) 16 (12)
Diuretics 134 (100) 7 (5)
Associated lesions, n (%) 134 (100) 31 (23)
Atrial septal defect 134 (100) 16 (12)
Patent ductus arteriosus 133 (99) 11 (8)
Aortic valve stenosis 134 (100) 8 (6)
Surgical characteristics
Age at repair, years 134 (100) 3.3 [1.0–6.7
Prior aortopulmonary shunt, n (%) 134 (100) 39 (29)
Blalock shunt 134 (100) 20 (15)
Waterston shunt 134 (100) 16 (12)
Other shunt 134 (100) 3 (2)
Transannular patch used, n (%) 129 (96) 87 (67)
Re-intervention, n (%) 134 (100) 86 (64)
More than two re-interventions 134 (100) 14 (10)
Surgical, n (%) 134 (100) 75 (56)
Pulmonary valve replacement 134 (100) 67 (50)
Residual VSD repair 134 (100) 19 (14)
Catheter-based, n (%) 134 (100) 19 (14)
Pulmonary valve balloon dilatation 134 (100) 11 (8)
Pulmonary valve replacement 134 (100) 4 (3)
Ablation 134 (100) 4 (3)
Other, n (%) 134 (100) 22 (16)
Legend: Continuous variables are reported asmean± SD or asmedian [IQ1–IQ3], categorical var
normal (b34 mL/m2) and dilated (≥34 mL/m2) left atrium. Signiﬁcant P-values are printed in
comparisons. *In 13 patients the cardiac medication was changed during the follow-up.
Abbreviations: ACE, angiotensin converting enzyme; LA, left atrial; NYHA, New York Heart Ass
Please cite this article as: V.J.M. Baggen, et al., Prognostic value of left atrial
http://dx.doi.org/10.1016/j.ijcard.2017.02.153was 3.3 [1.0–6.7] years and in 87 patients (67%) a transannular patch
was used. Baseline characteristics are further detailed in Table 1.
The LA was dilated (≥34 mL/m2) in 58 patients (43%). Clinical char-
acteristics and results of electrocardiography and echocardiography are
compared between patients with a normal and a dilated LA in Tables 1
and 2. Patients with a dilated LA were signiﬁcantly older and were in a
higher NYHA functional class. In addition, 22 patients (38%) with a
dilated LA used cardiac medication compared with 9 patients (12%)
with a normal LA (P b 0.001). The majority of patients were in sinus
rhythm (n = 111, 83%) and had a prolonged QRS interval (n = 91,
75%). None of the patients fulﬁlled criteria of heart failure at baseline.
Patients with a dilated LA had signiﬁcantly larger LV volumes, impaired
diastolic function (expressed by a lower E’wave and a higher E/E’-ratio),
a larger RV end-diastolic annulus dimension and a higher NT-proBNP
level. No signiﬁcant differences in rhythm or valvular function were
found between both subgroups.
3.2. Follow-up
At the end of the follow-up (August 1, 2015), survival status and
detailed follow-up data were complete in 134 patients (100%). During
amedian follow-up period of 40.4 [31.9–46.7]months, the primary end-
point occurred in 33 patients (25%) and the secondary endpoint
occurred in 8 patients (6%). None of the patients with a normally sizedLA volume index, mL/m2
b34 (normal, n = 76) ≥34 (dilated, n = 58) P-value
31 [26–39] 42 [34–49] b0.001
49 (65) 38 (66) 0.900
3 (4) 9 (16) 0.020
24 ± 4 25 ± 4 0.046
1.89 ± 0.22 1.89 ± 0.18 0.918
124 ± 15 127 ± 19 0.355
1 (1) 0 (0) -
9 (12) 22 (38) b0.001
4 (5) 6 (10) -
3 (4) 14 (24) -
2 (3) 8 (14) -
2 (3) 8 (14) -
1 (1) 15 (26) -
0 (0) 7 (12) -
15 (20) 16 (28) 0.286
7 (9) 9 (16) -
7 (9) 4 (7) -
4 (5) 5 (7) -
] 1.6 [0.8–4.1] 5.8 [2.2–9.7] b0.001
14 (18) 25 (43) 0.002
5 (7) 15 (26) -
7 (9) 9 (16) -
2 (2) 1 (2) -
52 (71) 35 (63) 0.294
48 (63) 38 (66) 0.778
4 (5) 10 (17) 0.025
46 (61) 29 (50) 0.224
42 (55) 25 (43) -
8 (11) 11 (19) -
11 (15) 8 (14) 0.911
7 (9) 4 (7) -
2 (3) 2 (3) -
2 (3) 2 (3) -
9 (12) 13 (22) 0.102
iables are reported as n (%). P-values are given for the comparison between patients with a
bold. Comparisons were not made between subgroups, in order to avoid multiplicity of
ociation; VSD, ventricular septal defect.
size and function in adults with tetralogy of Fallot, Int J Cardiol (2017),
Table 2
Baseline electrocardiography, echocardiography and laboratory results of the study cohort.
LA volume index, mL/m2
Valid cases, n (%) All patients b34 (normal, n = 76) ≥34 (dilated, n = 58) P-value
Electrocardiography
Heart rate, beats/min 134 (100) 75 ± 13 76 ± 14 73 ± 13 0.298
Rhythm, n (%)
Sinus rhythm 134 (100) 111 (83) 67 (88) 44 (76) 0.061
Pacemaker rhythm 134 (100) 12 (9) 4 (5) 8 (14) 0.087
Other* 134 (100) 11 (8) 5 (7) 6 (10) 0.531
QRS duration, ms† 122 (91) 144 [120–169] 139 [119–164] 158 [122–170] 0.286
QRS duration N120 ms, n (%)* 122 (91) 91 (75) 52 (72) 39 (78) 0.471
RBBB 91 (100) 82 (90) 50 (96) 32 (82) -
LBBB 91 (100) 1 (1) 0 (0) 1 (3) -
Other 91 (100) 8 (9) 2 (4) 6 (15) -
PR interval, if sinus rhythm, ms 111 (83) 165 [146–180] 163 [146–173] 173 [148–187] 0.053
Echocardiography
LV end diastolic volume, mL/m2 122 (91) 56 [49–66] 54 [45–64] 59 [51–71] 0.027
LV end systolic volume, mL/m2 121 (90) 25 [20−32] 24 [21−30] 28 [21–34] 0.048
LV ejection fraction, % 122 (91) 53 ± 8 54 ± 5 53 ± 10 0.446
Normal LV function, n (%) 134 (100) 58 (43) 33 (43) 25 (43) 0.971
E/A-ratio 128 (95) 1.5 [1.1–2.1] 1.5 [1.1–2.1] 1.4 [1.1–2.0] 0.338
E’ wave, cm/s 129 (96) 7.7 [6.2–9.2] 8.1 [6.6–9.6] 7.0 [5.8–8.8] 0.023
E/E’-ratio 127 (95) 10.0 [8.1–13.6] 8.9 [7.7–11.9] 11.3 [8.4–15.8] 0.005
Deceleration time, ms 124 (93) 192 [158–235] 192 [158–237] 192 [159–235] 0.835
RV end-diastolic annulus, mm 119 (89) 45.7 ± 7.9 43.7 ± 7.7 48.4 ± 7.4 0.001
TAPSE, mm 124 (93) 17.4 ± 4.5 17.1 ± 4.4 17.8 ± 4.8 0.432
RV fractional area change, % 105 (78) 41 ± 9 41 ± 9 42 ± 9 0.443
Valvular function
AV peak velocity, m/s 117 (87) 1.07 [0.94–1.21] 1.05 [0.91–1.16] 1.12 [0.96–1.24] 0.078
AR ≥moderate, n (%) 89 (66) 3 (3) 0 (0) 3 (7) 0.101
PV peak velocity, m/s 131 (98) 2.20 ± 0.75 2.24 ± 0.73 2.15 ± 0.78 0.519
PR ≥moderate, n (%) 124 (93) 47 (38) 25 (37) 22 (39) 0.773
TR ≥moderate, n (%) 124 (93) 11 (9) 5 (7) 6 (11) 0.536
TR peak velocity, m/s 107 (80) 2.8 ± 0.5 2.8 ± 0.5 2.9 ± 0.6 0.276
MR ≥moderate, n (%) 82 (61) 1 (1) 0 (0) 1 (2) 1.000
Laboratory results
Hemoglobin, mmol/L 93 (69) 9.2 ± 0.9 9.3 ± 0.8 9.0 ± 1.0 0.181
Creatinine, μmol/L 134 (100) 78.4 ± 19.5 76.7 ± 13.7 80.7 ± 25.2 0.237
NT-proBNP, pmol/L 133 (99) 14.5 [6.4–27.4] 9.3 [4.9–17.0] 23.4 [14.6–42.4] b0.001
Legend: As deﬁned in Table 1. *Three patients were in atrial ﬁbrillation (one with LA volume index b34 mL/m2 and two with LA volume index ≥34 mL/m2). †Patients with a pacemaker
rhythm were excluded.
Abbreviations: AR, aortic regurgitation; AV, aortic valve; LA, left atrial; LBBB, left bundle branch block; LV, left ventricle; MR, mitral regurgitation; NT-pro-BNP, N-terminal pro-B-type na-
triuretic peptide; PR, pulmonary regurgitation; PV, pulmonary valve; RBBB, right bundle branch block; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid
regurgitation.
4 V.J.M. Baggen et al. / International Journal of Cardiology xxx (2017) xxx–xxxLAdied or developedheart failure. Kaplan-Meier estimates of event-free
survival (the primary endpoint) were 88% at year one, 83% at year two
and 77% at year three. Heart-failure-free survival (the secondaryFig. 1. Cardiovascular event-free survival and heart failure-free survival, stratiﬁ
Please cite this article as: V.J.M. Baggen, et al., Prognostic value of left atrial
http://dx.doi.org/10.1016/j.ijcard.2017.02.153endpoint) was 96% at year one, 96% at year two and 94% at year three.
All components of the primary and secondary endpoint are separately
displayed in Supplemental File 2 for exploratory purposes.ed according to LA maximal volume index (b34 mL/m2 and ≥34 mL/m2).
size and function in adults with tetralogy of Fallot, Int J Cardiol (2017),
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In Fig. 1, Kaplan-Meier curves show the proportion of patients free of
the primary and secondary endpoint for patients with a normal and a di-
lated LA. In patients with a normally sized LA, the cumulative proportion
of death and heart failure was 0%. In Table 3, the association between all
LA measurements and the primary endpoint is shown. Except for the
anteroposterior dimension on the parasternal long-axis view, all other
LA size measurements (length, area, and volume) were signiﬁcantly as-
sociated with the primary endpoint, also when adjusted for age and
NYHA functional class. The standardized adjusted hazard ratios (HRs)
show that among the various LA size indices, LA lengthwasmost strong-
ly associated with the primary endpoint (HR 2.05 [95% CI 1.38–3.02],
P b 0.001). In addition, a lower reservoir function (TEF) and a lower con-
tractile function (AEF) were signiﬁcantly associated with the primary
endpoint, whereas a lower conduit function (PEF) was not.
3.4. Reproducibility of left atrial measurements
Bland-Altman plots of the intra- and inter-observer agreement of LA
maximal volume, area and length are presented in Supplemental File 3.
Mean differences of the intra-observer measurements were −0.3 ±
0.9 mL/m2 (COV = 2.5), 0.0 ± 0.4 cm2/m2 (COV = 3.4) and 0.0 ±
0.2 cm/m2 (COV = 5.7), and mean relative differences were −0.7 ±
2.8%,−0.2 ± 3.5% and−0.4 ± 5.7% for LA maximal volume, area, and
length, respectively. Mean differences of the inter-observer measure-
ments were −0.3 ± 5.2 mL/m2 (COV = 14.2), 0.0 ± 1.0 cm2/m2
(COV = 8.4) and 0.0 ± 0.2 cm/m2 (COV = 5.8), and mean relative
differences were−0.5 ± 15.1%,−0.2 ± 8.9% and−0.8 ± 5.6% for LA
maximal volume, area, and length, respectively.
4. Discussion
To the best of our knowledge, this is theﬁrst study that evaluates the
prognostic value of LA size and function in ToF patients. In our cohort ofTable 3
The association of left atrial size and function with the primary composite endpoint.
Valid cases,
n (%)




AP dimension, cm† 124 (93) 3.9 ± 0.8 2.59 (1.80–3.73) b0.001
AP dimension, cm/m2† 124 (93) 2.1 ± 0.4 3.85 (1.97–7.53) b0.001
Length, cm† 134 (100) 5.5 ± 0.8 3.38 (2.10–5.42) b0.001
Length, cm/m2† 134 (100) 2.9 ± 0.5 4.47 (2.06–9.72) b0.001
Area, cm2/m2 134 (100) 11.5 ± 2.6 1.35 (1.21–1.50) b0.001
Maximal volume ≥ 34 mL/m2 134 (100) - 3.71 (1.76–7.80) 0.001
Maximal volume, mL/m2 134 (100) 36.0 ± 12.6 1.06 (1.04–1.08) b0.001
Minimal volume, mL/m2‡ 130 (97) 20.1 ± 10.0 1.06 (1.04–1.09) b0.001
Pre-A-wave volume, mL/m2‡ 129 (96) 25.6 ± 9.8 1.07 (1.04–1.10) b0.001
LA function
Reservoir function
TEV, mL/m2 130 (97) 16.1 ± 5.2 1.06 (1.00–1.13) 0.070
TEF, % 130 (97) 45.5 ± 9.2 0.94 (0.91–0.97) b0.001
Expansion index, % 130 (97) 88.4 ± 31.1 0.98 (0.96–0.99) 0.000
Conduit function
PEV, mL/m2 129 (96) 9.7 ± 4.0 1.07 (0.98–1.16) 0.127
PEF, % 129 (96) 27.9 ± 9.0 0.97 (0.93–1.01) 0.087
Contractile function
AEV, mL/m2 127 (95) 6.4 ± 2.8 1.11 (0.99–1.25) 0.071
AEF, % 127 (95) 25.1 ± 7.6 0.94 (0.90–0.98) 0.008
Legend: *Adjusted for age and NYHA functional class. †LA anteroposterior dimension was me
chamber view. ‡Minimal volume was not measured in patients with inadequate echocardiogra
ﬁbrillation (n=3) or inadequate echocardiographic image quality (n=2). Signiﬁcant P-values
ing LA measurement.
Abbreviations: AEF, active emptying fraction; AEV, active emptying volume; AP, anteroposterio
PEV, passive emptying volume; TEF, total emptying fraction; TEV, total emptying volume.
Please cite this article as: V.J.M. Baggen, et al., Prognostic value of left atrial
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patients. Larger LA size, lower LA reservoir function, and lower LA
contractile functionwere signiﬁcantly associatedwith the primary end-
point of any cardiovascular event. None of the patients with a normally
sized LA died or developed heart failure. Among the different indices of
LA size, LA lengthwasmost strongly associated with adverse cardiovas-
cular events, and had the best reproducibility.
4.1. Diastolic dysfunction
A potential association of LA size and clinical outcomes in patients
with repaired ToF has been suggested earlier, but this association has
not further been described [15]. However fromother cardiac conditions,
as well as in the general population, it is known that LA size is a marker
of LV diastolic dysfunction and that it is associated with adverse clinical
outcome [7–10,16,17]. In our cohort, patients with a dilated LA were
signiﬁcantly older, had larger LV volumes, and indeed had an impaired
diastolic function. Of note, the accuracy of LV diastolic parameters
such as the E’ wave is questioned in patients with ToF because of the
presence of the interventricular septal patch. Evaluation of LA size
may therefore be a more reliable alternative, or valuable addition to
the set of LV diastolic function parameters.
Cardiac magnetic resonance studies have evaluated the extent of
ventricular ﬁbrosis in patients with ToF using late gadolinium enhance-
ment [18,19]. In this relatively young patient group,more prominent LV
regional and diffuse myocardial ﬁbrosis was observed, which was
related to both abnormal systolic and diastolic function. Increasedmyo-
cardial ﬁbrosis may explain why LV diastolic dysfunction and accompa-
nied LA enlargement already develops at a relatively young age in
patients with ToF [18,19]. However, the normal aging process is
also likely to play a role in the development of diastolic dysfunction,
which was reﬂected in our cohort by increased LA volumes in older
patients.
In this study, a decreased LA active emptying fractionwas associated








2.00 (1.25–3.21) 0.004 2.16 (1.61–2.90) b0.001 1.75 (1.20–2.57) 0.004
2.10 (0.86–5.12) 0.102 1.82 (1.35–2.45) b0.001 1.39 (0.94–2.07) 0.102
2.49 (1.51–4.09) b0.001 2.60 (1.79–3.77) b0.001 2.05 (1.38–3.02) b0.001
2.87 (1.26–6.54) 0.012 2.00 (1.39–2.86) b0.001 1.63 (1.11–2.38) 0.012
1.24 (1.07–1.43) 0.004 2.16 (1.65–2.84) b0.001 1.73 (1.20–2.51) 0.004
2.48 (1.09–5.62) 0.030 - - - -
1.04 (1.01–1.07) 0.007 2.06 (1.61–2.64) b0.001 1.63 (1.14–2.33) 0.007
1.04 (1.01–1.07) 0.006 1.85 (1.51–2.26) b0.001 1.51 (1.13–2.03) 0.006
1.06 (1.02–1.10) 0.003 1.93 (1.52–2.45) b0.001 1.75 (1.21–2.51) 0.003
1.02 (0.95–1.09) 0.603 1.36 (0.98–1.89) 0.070 1.10 (0.78–1.54) 0.603
0.96 (0.93–0.99) 0.008 0.57 (0.43–0.74) b0.001 0.67 (0.50–0.90) 0.008
0.98 (0.97–1.00) 0.007 0.47 (0.32–0.70) b0.001 0.59 (0.39–0.86) 0.007
1.05 (0.97–1.14) 0.234 1.30 (0.93–1.82) 0.127 1.22 (0.88–1.71) 0.234
0.99 (0.95–1.03) 0.482 0.74 (0.53–1.05) 0.087 0.88 (0.61–1.26) 0.482
0.99 (0.86–1.14) 0.883 1.35 (0.97–1.88) 0.071 0.97 (0.65–1.44) 0.883
0.92 (0.87–0.96) 0.001 0.62 (0.44–0.88) 0.008 0.51 (0.34–0.76) 0.001
asured on the parasternal long axis view, and LA length was measured on the apical four
phic image quality (n= 4); pre-A-wave volume was not measured in patients with atrial
are printed in bold. StandardizedHRs are expressed per one SD increase in the correspond-
r; CI, conﬁdence interval; HR, hazard ratio; LA, left atrial; PEF, passive emptying fraction;
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6 V.J.M. Baggen et al. / International Journal of Cardiology xxx (2017) xxx–xxxnot. This association has also been described in the general population,
in chronic hypertension, and in ischemic heart disease [13,20].When LV
diastolic dysfunction progresses, adequate diastolic ﬁlling of the LV
becomes more dependent on the contractile function of the LA [20].
This might explain why the contribution of the LA active emptying
fraction seems to be of clinical importance in patients with ToF, in con-
trast to the passive emptying fraction. This is in line with a previous
study in asymptomatic young patients after ToF repair, in which earlier
and increased LA active contraction was suggested to indicate adaptive
compensatory mechanisms to overcome latent and asymptomatic
altered LV performance [21].4.2. Left atrial enlargement and clinical worsening
RV dilatation and dysfunction have always been the major concern
in patients with repaired ToF [1]. More recently, LV systolic dysfunction
has also shown to predict adverse outcomes in ToF patients [5,22,23].
Several studies showed an association between RV and LV systolic
dysfunction in ToF patients, suggesting anunfavorable ventricular inter-
action [5,24,25]. For instance, RV dilatation - secondary to RV volume
overload - may shift the interventricular septum to the left, changing
LV geometry, mechanics and ﬁlling [26]. More speciﬁc, speckle-
tracking echocardiography studies have suggested that RV dilatation im-
pedes LV apical rotation in patients with repaired ToF. The subsequent
reduced LV twist resulted in global LV systolic dysfunction [24,25,27]. In-
terestingly, the abnormal systolic LV twistwas also related to LV diastolic
dysfunction in these patients [24]. Diastolic dysfunction can lead to an
increase in LA pressure, reﬂected by LA enlargement. The resulting in-
crease in pulmonary artery pressuremay augment pulmonary regurgita-
tion, which is a common problem in ToF patients [1]. The subsequent RV
dilatation may create one of the vicious circles that can tilt a stable ToF
patient towards progressive clinical deterioration.
Atrial ﬁbrillation and mitral regurgitation are also known to
inﬂuence the LA size [28]. In patients with ToF, atrial ﬁbrillation is an
important cause of morbidity and poor clinical outcome [15,28,29]. LA
dilatation in patients with mitral regurgitation has been described as a
compensatory mechanism and predictor of cardiovascular events [28,
29]. Both conditions could in theory explain the association of LA
enlargement and clinical deterioration. However, in our cohort they
do not seem to play a major role, since we found no signiﬁcant
differences in rhythm and heart rate between patients with a normal
and a dilated LA, only three patients were in atrial ﬁbrillation, and
only one patient had moderate mitral regurgitation.4.3. Comparison of left atrial size measurements
According to the guidelines, the most reliable and accurate meth-
od to estimate LA size and function is provided by LA volume or by
multiple linear dimensions. A single linear measurement of the LA
may underestimate LA size, considering the asymmetrical shape
and the possibility of foreshortening [8,12,16,30]. In order to com-
pare the prognostic value of the different measurements of LA size
(volume, area, length, and anteroposterior dimension), we evaluated
eachmeasurement as a standardized variable, which allows compar-
ison of the HRs across all variables. Interestingly, a single measure-
ment of LA length appeared to be more predictive than LA volume,
reﬂected by a higher standardized HR. This could be explained
by the observation that LA dilatation mainly develops in the
craniocaudal direction. Anatomic factors such as a dilated right ven-
tricle, the sternum and the spine may limit LA dilatation in the
anteroposterior direction [31]. As a result, LA length possibly provides a
better reﬂection of LA enlargement. In addition, LA length showed to be
the most reproducible measurement, reﬂected by a smaller inter-
observer variation than the LA area or volume measurement.Please cite this article as: V.J.M. Baggen, et al., Prognostic value of left atrial
http://dx.doi.org/10.1016/j.ijcard.2017.02.1534.4. Clinical implications
In patients with ToF, accurate risk prediction is of paramount
importance in order to optimize individual follow-up strategies, phar-
macological treatment and timing of interventions [1]. This study
shows that one-dimensional LA length is a simple and reliablemeasure-
ment, which is associated with cardiovascular events in clinically stable
adults with repaired ToF. This measurement comes at no extra costs, as
it is quick and can be performed on the A4C view of routinely acquired
echocardiographic images. Although other imaging techniques such as
CT, CMR or 3D echocardiography could provide amore accurate estima-
tion of LA size, this simple linear dimension can be easily implemented
in day-to-day clinical practice. Patients with LA dilatation may require
more vigilant follow-up, initiation or expansion of medical therapy, or
earlier timing of a re-intervention. Importantly, LA size seems to have
a very high negative predictive value for death and heart failure,
which makes it particularly valuable as a screening tool. Patients with
a normally sized LA may be reassured, and may need less frequent
evaluation at the outpatient clinic.
4.5. Study limitations
The most important limitation of this study is that LA volumes were
measured using a single plane approach of the A4C only, because the
two-chamber views were of insufﬁcient quality in the majority of
patients. Because of this limitation, the LA volumes measured in our
study could be slightly underestimated [31]. Second, due to the limited
number of events, we could only adjust for the variables age and NYHA
functional class, which may have resulted in residual confounding. Age
at initial repair and prior palliative shunts were associated with LA
dilatation, andmay also play a crucial role. Larger studies are warranted
to investigate the prognostic value of LA size and function in addition to
multiple clinical, echocardiographic and biochemical markers.
5. Conclusions
In this cohort of clinically stable adults with repaired ToF, the LAwas
enlarged in a substantial number of patients. LA size and function,
measured on routine echocardiographic examination, were signiﬁcant-
ly associated with cardiovascular events. A normally sized LA could
accurately rule out the risk of death and heart failure with a high
negative predictive value. LA length was most strongly associated with
cardiovascular events, and had the best reproducibility. This free,
quick and simple one-dimensional echocardiographic measurement
may therefore be a valuable additional tool in the management and
risk stratiﬁcation of adults with repaired ToF.
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